Clinical Trial Update: A PK Study to Compare GME751 (Proposed Pembrolizumab Biosimilar) and US-licensed and EU-authorized Keytruda® in Participants With Stage II and III Melanoma [Phase 1]

View source ↗

Summary

A phase 1 PK study comparing GME751, a proposed pembrolizumab biosimilar by Sandoz, to Keytruda in participants with stage II-III melanoma; trial status is acti…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• GME751
• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: Sandoz | Conditions: Melanoma | Phase 1 | Status: ACTIVE_NOT_RECRUITING